On the heels of the first successful round of negotiated prices, Medicare has selected 15 additional high-cost drugs for price negotiations, with savings expected in 2027.
The list includes treatments for Type 2 diabetes, HIV, psoriasis, and severe arthritis. Negotiated prices could reduce out-of-pocket costs for millions of seniors who depend on these brand-name medications.
While the actual discounts won’t kick in until next year, beneficiaries should review their plan’s formulary notices this fall to anticipate changes.
